You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameTrazodone
Accession NumberDB00656  (APRD00533)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionA serotonin uptake inhibitor that is used as an antidepressive agent. It has been shown to be effective in patients with major depressive disorders and other subsets of depressive disorders. It is generally more useful in depressive disorders associated with insomnia and anxiety. This drug does not aggravate psychotic symptoms in patients with schizophrenia or schizoaffective disorders. (From AMA Drug Evaluations Annual, 1994, p309)
Structure
Thumb
Synonyms
2-(3-[4-(3-Chlorophenyl)-1-piperazinyl]propyl)[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one
Trazodona
Trazodone
Trazodonum
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Desyrel Dividose Tab 300mgTablet300 mgOralBristol Labs Division Of Bristol Myers Squibb1989-12-311999-08-09Canada
Desyrel Dividose Tablet 150 mgTablet150 mgOralBristol Myers Squibb Canada1988-12-312010-01-05Canada
Desyrel Tab 100mgTablet100 mgOralBristol Myers Squibb Canada1983-12-312010-09-07Canada
Desyrel Tab 50mgTablet50 mgOralBristol Myers Squibb Canada1983-12-312010-05-14Canada
Dom-trazodone Tablets - 50mgTablet50 mgOralDominion Pharmacal1996-12-31Not applicableCanada
Dom-trazodone Tablets-100mgTablet100 mgOralDominion Pharmacal1996-12-31Not applicableCanada
Mar-trazodoneTablet50 mgOralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Mar-trazodoneTablet100 mgOralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Mar-trazodoneTablet150 mgOralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Mylan-trazodoneTablet50 mgOralMylan Pharmaceuticals Ulc1997-09-052016-06-28Canada
Mylan-trazodoneTablet100 mgOralMylan Pharmaceuticals Ulc1997-09-052016-06-28Canada
Mylan-trazodoneTablet150 mgOralMylan Pharmaceuticals Ulc1997-11-282016-06-28Canada
Ntp-trazodoneTablet150 mgOralTeva Canada LimitedNot applicableNot applicableCanada
Ntp-trazodoneTablet50 mgOralTeva Canada LimitedNot applicableNot applicableCanada
Ntp-trazodoneTablet100 mgOralTeva Canada LimitedNot applicableNot applicableCanada
Nu-trazodone - Tab 100mgTablet100 mgOralNu Pharm Inc1995-12-312012-09-04Canada
Nu-trazodone - Tab 50mgTablet50 mgOralNu Pharm Inc1995-12-312012-09-04Canada
Nu-trazodone-D - Tab 150mgTablet150 mgOralNu Pharm Inc1995-12-312012-09-04Canada
OleptroTablet, extended release150 mg/1OralAngelini Pharma Inc.2010-02-022016-03-29Us
OleptroTablet, extended release300 mg/1OralAngelini Pharma Inc.2010-02-022016-03-29Us
OleptroTablet, extended release150 mgOralAngelini Pharma Inc2011-03-09Not applicableCanada
OleptroTablet, extended release300 mgOralAngelini Pharma Inc2011-03-09Not applicableCanada
Penta-trazodone TabletsTablet100 mgOralPentapharm Ltd.Not applicableNot applicableCanada
Penta-trazodone TabletsTablet150 mgOralPentapharm Ltd.Not applicableNot applicableCanada
Penta-trazodone TabletsTablet50 mgOralPentapharm Ltd.Not applicableNot applicableCanada
PHL-trazodoneTablet50 mgOralPharmel Inc1998-02-17Not applicableCanada
PHL-trazodoneTablet100 mgOralPharmel Inc1998-02-17Not applicableCanada
PMS Trazodone HCl Tab 100mgTablet100 mgOralPharmascience Inc1993-12-31Not applicableCanada
PMS Trazodone HCl Tab 50mgTablet50 mgOralPharmascience Inc1993-12-31Not applicableCanada
PMS-trazodoneTablet75 mgOralPharmascience Inc1998-02-17Not applicableCanada
Ratio-trazodoneTablet100 mgOralTeva Canada Limited2006-03-10Not applicableCanada
Ratio-trazodoneTablet150 mgOralTeva Canada Limited2006-03-10Not applicableCanada
Ratio-trazodoneTablet50 mgOralTeva Canada Limited2006-03-10Not applicableCanada
Ratio-trazodone Tab 150mgTablet150 mgOralRatiopharm Inc Division Of Teva Canada Limited1994-12-312009-01-22Canada
Ratio-trazodone Tablets 100mgTablet100 mgOralRatiopharm Inc Division Of Teva Canada Limited1994-12-312009-01-22Canada
Ratio-trazodone Tablets 50mgTablet50 mgOralRatiopharm Inc Division Of Teva Canada Limited1994-12-312009-01-22Canada
Scheinpharm TrazodoneTablet50 mgOralSchein Pharmaceutical Canada Inc.2000-09-132004-07-26Canada
Scheinpharm TrazodoneTablet100 mgOralSchein Pharmaceutical Canada Inc.2000-09-132004-07-26Canada
Teva-trazodoneTablet100 mgOralTeva Canada Limited1995-12-31Not applicableCanada
Teva-trazodoneTablet50 mgOralTeva Canada Limited1995-12-31Not applicableCanada
Teva-trazodoneTablet150 mgOralTeva Canada Limited1995-12-31Not applicableCanada
TrazodoneTablet150 mgOralSanis Health Inc2010-04-30Not applicableCanada
TrazodoneTablet50 mgOralSanis Health Inc2010-04-30Not applicableCanada
TrazodoneTablet100 mgOralSanis Health Inc2010-04-30Not applicableCanada
Trazodone - 100 - Tab 100mgTablet100 mgOralPro Doc Limitee1996-12-31Not applicableCanada
Trazodone-150 D - Tab 150mgTablet150 mgOralPro Doc Limitee1996-12-31Not applicableCanada
Trazodone-50 - Tab 50mgTablet50 mgOralPro Doc Limitee1996-12-31Not applicableCanada
TrazorelTablet150 mgOralValeant Canada Lp Valeant Canada S.E.C.1997-02-042014-07-30Canada
TrazorelTablet50 mgOralValeant Canada Lp Valeant Canada S.E.C.1997-02-042014-07-30Canada
TrazorelTablet100 mgOralValeant Canada Lp Valeant Canada S.E.C.1997-03-072014-07-30Canada
Zym-trazodoneTablet100 mgOralZymcan Pharmaceuticals Inc2009-06-232014-06-16Canada
Zym-trazodoneTablet68.25 mgOralZymcan Pharmaceuticals Inc2004-04-062014-06-16Canada
Zym-trazodoneTablet50 mgOralZymcan Pharmaceuticals Inc2009-06-232014-06-16Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-trazodone D Tablets 150mgTablet150 mgOralApotex Inc1995-12-31Not applicableCanada
Apo-trazodone Tablets 100mgTablet100 mgOralApotex Inc1995-12-31Not applicableCanada
Apo-trazodone Tablets 50mgTablet50 mgOralApotex Inc1995-12-31Not applicableCanada
TrazodoneTablet50 mg/1OralNorthwind Pharmaceuticals, LLC2014-12-01Not applicableUs
Trazodone HydrochlorideTablet100 mg/1OralBlenheim Pharmacal, Inc.2012-01-18Not applicableUs
Trazodone HydrochlorideTablet, film coated100 mg/1OralMutual Pharmaceutical Company, Inc.1993-03-24Not applicableUs
Trazodone HydrochlorideTablet150 mg/1OralCardinal Health1990-09-30Not applicableUs
Trazodone HydrochlorideTablet50 mg/1OralProficient Rx LP1990-09-30Not applicableUs
Trazodone HydrochlorideTablet150 mg/1OralAmerican Health Packaging2012-09-03Not applicableUs
Trazodone HydrochlorideTablet50 mg/1OralAidarex Pharmaceuticals LLC1990-09-30Not applicableUs
Trazodone HydrochlorideTablet, film coated150 mg/1OralA S Medication Solutions1993-03-24Not applicableUs
Trazodone HydrochlorideTablet, film coated100 mg/1OralREMEDYREPACK INC.2016-01-07Not applicableUs
Trazodone HydrochlorideTablet, film coated50 mg/1OralREMEDYREPACK INC.2016-08-31Not applicableUs
Trazodone HydrochlorideTablet100 mg/1OralREMEDYREPACK INC.2016-11-17Not applicableUs
Trazodone HydrochlorideTablet50 mg/1OralKAISER FOUNDATION HOSPITALS1987-12-22Not applicableUs
Trazodone HydrochlorideTablet100 mg/1OralLake Erie Medical DBA Quality Care Products LLC2011-12-14Not applicableUs
Trazodone HydrochlorideTablet50 mg/1OralCardinal Health2004-02-03Not applicableUs
Trazodone HydrochlorideTablet100 mg/1OralGolden State Medical Supply, Inc.2008-11-17Not applicableUs
Trazodone HydrochlorideTablet50 mg/1OralDispensing Solutions, Inc.2011-01-20Not applicableUs
Trazodone HydrochlorideTablet50 mg/1OralSTAT RX LLC USA1987-12-11Not applicableUs
Trazodone HydrochlorideTablet50 mg/1OralTeva Pharmaceuticals Usa, Inc.1990-09-30Not applicableUs
Trazodone HydrochlorideTablet50 mg/1OralA S Medication Solutions1990-09-30Not applicableUs
Trazodone HydrochlorideTablet, film coated150 mg/1OralA S Medication Solutions1993-03-24Not applicableUs
Trazodone HydrochlorideTablet50 mg/1OralAv Kare, Inc.2014-02-06Not applicableUs
Trazodone HydrochlorideTablet100 mg/1OralAphena Pharma Solutions Tennessee, Llc2014-02-06Not applicableUs
Trazodone HydrochlorideTablet150 mg/1OralPreferred Pharmaceuticals Inc.2016-06-15Not applicableUs
Trazodone HydrochlorideTablet50 mg/1OralTorrent Pharmaceuticals Limited2013-11-27Not applicableUs
Trazodone HydrochlorideTablet50 mg/1OralPhysicians Total Care, Inc.1996-04-09Not applicableUs
Trazodone HydrochlorideTablet50 mg/1OralClinical Solutions Wholesale1990-09-30Not applicableUs
Trazodone HydrochlorideTablet100 mg/1Oralbryant ranch prepack2011-01-20Not applicableUs
Trazodone HydrochlorideTablet100 mg/1OralLegacy Pharmaceutical Packaging2008-11-17Not applicableUs
Trazodone HydrochlorideTablet, film coated50 mg/1OralAphena Pharma Solutions Tennessee, Llc2010-05-30Not applicableUs
Trazodone HydrochlorideTablet150 mg/1OralApotex Corp2008-11-17Not applicableUs
Trazodone HydrochlorideTablet100 mg/1OralContract Pharmacy Services Pa2010-08-11Not applicableUs
Trazodone HydrochlorideTablet100 mg/1OralRebel Distributors Corp.1987-12-11Not applicableUs
Trazodone HydrochlorideTablet150 mg/1OralCarilion Materials Management1990-09-30Not applicableUs
Trazodone HydrochlorideTablet, film coated50 mg/1OralREMEDYREPACK INC.2015-11-06Not applicableUs
Trazodone HydrochlorideTablet50 mg/1OralClinical Solutions Wholesale, Llc1990-09-30Not applicableUs
Trazodone HydrochlorideTablet, film coated50 mg/1OralA S Medication Solutions1993-03-24Not applicableUs
Trazodone HydrochlorideTablet100 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2011-01-20Not applicableUs
Trazodone HydrochlorideTablet50 mg/1OralUnit Dose Services2011-01-20Not applicableUs
Trazodone HydrochlorideTablet150 mg/1OralCardinal Health1990-09-30Not applicableUs
Trazodone HydrochlorideTablet150 mg/1OralBlenheim Pharmacal, Inc.2010-03-03Not applicableUs
Trazodone HydrochlorideTablet, film coated150 mg/1OralMutual Pharmaceutical Company, Inc.1993-03-24Not applicableUs
Trazodone HydrochlorideTablet100 mg/1OralCardinal Health2008-11-17Not applicableUs
Trazodone HydrochlorideTablet100 mg/1OralProficient Rx LP1990-09-30Not applicableUs
Trazodone HydrochlorideTablet50 mg/1OralKeltman Pharmaceuticals Inc.2010-11-17Not applicableUs
Trazodone HydrochlorideTablet100 mg/1OralAidarex Pharmaceuticals LLC1990-09-30Not applicableUs
Trazodone HydrochlorideTablet, film coated50 mg/1OralProficient Rx LP2010-05-30Not applicableUs
Trazodone HydrochlorideTablet150 mg/1OralREMEDYREPACK INC.2006-11-15Not applicableUs
Trazodone HydrochlorideTablet100 mg/1OralREMEDYREPACK INC.2016-10-07Not applicableUs
Trazodone HydrochlorideTablet150 mg/1OralREMEDYREPACK INC.2016-11-17Not applicableUs
Trazodone HydrochlorideTablet, film coated50 mg/1OralQualitest Pharmaceuticals2010-05-30Not applicableUs
Trazodone HydrochlorideTablet50 mg/1OralLake Erie Medical DBA Quality Care Products LLC2011-12-14Not applicableUs
Trazodone HydrochlorideTablet100 mg/1OralCardinal Health2004-02-03Not applicableUs
Trazodone HydrochlorideTablet150 mg/1OralGolden State Medical Supply, Inc.2008-11-17Not applicableUs
Trazodone HydrochlorideTablet50 mg/1OralContract Pharmacy Services Pa2010-08-11Not applicableUs
Trazodone HydrochlorideTablet100 mg/1OralSTAT RX LLC USA1987-12-11Not applicableUs
Trazodone HydrochlorideTablet100 mg/1OralTeva Pharmaceuticals Usa, Inc.1990-09-30Not applicableUs
Trazodone HydrochlorideTablet150 mg/1OralAv Pak2016-08-08Not applicableUs
Trazodone HydrochlorideTablet50 mg/1OralA S Medication Solutions2008-11-17Not applicableUs
Trazodone HydrochlorideTablet100 mg/1OralClinical Solutions Wholesale1990-09-30Not applicableUs
Trazodone HydrochlorideTablet100 mg/1OralTYA Pharmaceuticals1990-09-30Not applicableUs
Trazodone HydrochlorideTablet50 mg/1OralMc Kesson Contract Packaging2011-10-11Not applicableUs
Trazodone HydrochlorideTablet, film coated100 mg/1OralAphena Pharma Solutions Tennessee, Llc2010-05-30Not applicableUs
Trazodone HydrochlorideTablet100 mg/1OralAv Kare, Inc.2014-02-06Not applicableUs
Trazodone HydrochlorideTablet, film coated50 mg/1OralA S Medication Solutions2010-05-30Not applicableUs
Trazodone HydrochlorideTablet50 mg/1OralAvera Mc Kennan Hospital2015-03-02Not applicableUs
Trazodone HydrochlorideTablet100 mg/1OralTorrent Pharmaceuticals Limited2013-11-27Not applicableUs
Trazodone HydrochlorideTablet100 mg/1OralPhysicians Total Care, Inc.1997-05-08Not applicableUs
Trazodone HydrochlorideTablet50 mg/1OralCardinal Health1990-09-30Not applicableUs
Trazodone HydrochlorideTablet300 mg/1OralApotex Corp2009-01-05Not applicableUs
Trazodone HydrochlorideTablet, film coated50 mg/1OralAmerican Health Packaging2013-12-16Not applicableUs
Trazodone HydrochlorideTablet150 mg/1OralRebel Distributors Corp.1988-03-09Not applicableUs
Trazodone HydrochlorideTablet50 mg/1OralMajor Pharmaceuticals2008-11-17Not applicableUs
Trazodone HydrochlorideTablet100 mg/1OralPreferred Pharmaceuticals, Inc2012-02-28Not applicableUs
Trazodone HydrochlorideTablet100 mg/1OralClinical Solutions Wholesale, Llc1990-09-30Not applicableUs
Trazodone HydrochlorideTablet50 mg/1OralDIRECT RX2014-01-01Not applicableUs
Trazodone HydrochlorideTablet50 mg/1OralMajor Pharmaceuticals2004-02-03Not applicableUs
Trazodone HydrochlorideTablet50 mg/1OralBlenheim Pharmacal, Inc.2011-04-01Not applicableUs
Trazodone HydrochlorideTablet, film coated50 mg/1OralA S Medication Solutions Llc2010-05-30Not applicableUs
Trazodone HydrochlorideTablet150 mg/1OralPd Rx Pharmaceuticals, Inc.1990-09-30Not applicableUs
Trazodone HydrochlorideTablet, film coated50 mg/1Oralbryant ranch prepack2010-05-30Not applicableUs
Trazodone HydrochlorideTablet100 mg/1OralKeltman Pharmaceuticals Inc.2010-11-17Not applicableUs
Trazodone HydrochlorideTablet150 mg/1OralAidarex Pharmaceuticals LLC1990-09-30Not applicableUs
Trazodone HydrochlorideTablet300 mg/1OralTeva Pharmaceuticals Usa, Inc..1999-05-03Not applicableUs
Trazodone HydrochlorideTablet50 mg/1OralREMEDYREPACK INC.2007-07-06Not applicableUs
Trazodone HydrochlorideTablet, film coated100 mg/1OralProficient Rx LP2010-05-30Not applicableUs
Trazodone HydrochlorideTablet100 mg/1OralAidarex Pharmaceuticals LLC1990-09-30Not applicableUs
Trazodone HydrochlorideTablet100 mg/1OralA S Medication Solutions2008-11-17Not applicableUs
Trazodone HydrochlorideTablet, film coated100 mg/1OralQualitest Pharmaceuticals2010-05-30Not applicableUs
Trazodone HydrochlorideTablet150 mg/1OralLake Erie Medical DBA Quality Care Products LLC1990-09-30Not applicableUs
Trazodone HydrochlorideTablet50 mg/1OralCardinal Health2011-01-202016-03-11Us
Trazodone HydrochlorideTablet50 mg/1OralApotex Corp2008-11-17Not applicableUs
Trazodone HydrochlorideTablet50 mg/1OralContract Pharmacy Services Pa2010-03-09Not applicableUs
Trazodone HydrochlorideTablet150 mg/1OralSTAT RX LLC USA1988-03-09Not applicableUs
Trazodone HydrochlorideTablet150 mg/1OralTeva Pharmaceuticals Usa, Inc.1990-09-30Not applicableUs
Trazodone HydrochlorideTablet100 mg/1OralCardinal Health2008-11-17Not applicableUs
Trazodone HydrochlorideTablet150 mg/1OralPhysicians Total Care, Inc.1992-02-20Not applicableUs
Trazodone HydrochlorideTablet150 mg/1OralClinical Solutions Wholesale1990-09-30Not applicableUs
Trazodone HydrochlorideTablet, film coated50 mg/1OralMed Vantx, Inc.1993-03-24Not applicableUs
Trazodone HydrochlorideTablet100 mg/1OralMc Kesson Contract Packaging2012-01-25Not applicableUs
Trazodone HydrochlorideTablet100 mg/1OralREMEDYREPACK INC.2010-09-282016-10-13Us
Trazodone HydrochlorideTablet150 mg/1OralAv Kare, Inc.2014-02-06Not applicableUs
Trazodone HydrochlorideTablet, film coated100 mg/1OralA S Medication Solutions2010-05-30Not applicableUs
Trazodone HydrochlorideTablet50 mg/1OralNu Care Pharmaceuticals, Inc.1990-09-30Not applicableUs
Trazodone HydrochlorideTablet150 mg/1OralTorrent Pharmaceuticals Limited2013-11-27Not applicableUs
Trazodone HydrochlorideTablet, film coated50 mg/1OralMutual Pharmaceutical Company, Inc.1993-03-24Not applicableUs
Trazodone HydrochlorideTablet100 mg/1OralCardinal Health1990-09-30Not applicableUs
Trazodone HydrochlorideTablet150 mg/1OralApotex Corp2014-12-31Not applicableUs
Trazodone HydrochlorideTablet, film coated100 mg/1OralAmerican Health Packaging2013-12-16Not applicableUs
Trazodone HydrochlorideTablet100 mg/1OralREMEDYREPACK INC.2013-03-272016-11-01Us
Trazodone HydrochlorideTablet100 mg/1OralMajor Pharmaceuticals2008-11-17Not applicableUs
Trazodone HydrochlorideTablet50 mg/1OralPreferred Pharmaceuticals, Inc2012-02-28Not applicableUs
Trazodone HydrochlorideTablet150 mg/1OralClinical Solutions Wholesale, Llc1990-09-30Not applicableUs
Trazodone HydrochlorideTablet100 mg/1OralDIRECT RX2014-01-01Not applicableUs
Trazodone HydrochlorideTablet100 mg/1OralMajor Pharmaceuticals2004-02-03Not applicableUs
Trazodone HydrochlorideTablet50 mg/1OralTYA Pharmaceuticals1990-09-30Not applicableUs
Trazodone HydrochlorideTablet150 mg/1OralBlenheim Pharmacal, Inc.2014-05-22Not applicableUs
Trazodone HydrochlorideTablet, film coated100 mg/1OralA S Medication Solutions Llc2010-05-30Not applicableUs
Trazodone HydrochlorideTablet50 mg/1OralPd Rx Pharmaceuticals, Inc.1990-09-30Not applicableUs
Trazodone HydrochlorideTablet150 mg/1Oralbryant ranch prepack1990-09-30Not applicableUs
Trazodone HydrochlorideTablet50 mg/1OralLegacy Pharmaceutical Packaging2008-11-17Not applicableUs
Trazodone HydrochlorideTablet50 mg/1OralSTAT Rx USA LLC2008-11-17Not applicableUs
Trazodone HydrochlorideTablet50 mg/1OralREMEDYREPACK INC.2008-01-29Not applicableUs
Trazodone HydrochlorideTablet50 mg/1OralAphena Pharma Solutions Tennessee, Llc2014-02-06Not applicableUs
Trazodone HydrochlorideTablet100 mg/1OralPd Rx Pharmaceuticals, Inc.1990-09-30Not applicableUs
Trazodone HydrochlorideTablet50 mg/1OralCardinal Health2008-11-17Not applicableUs
Trazodone HydrochlorideTablet150 mg/1OralA S Medication Solutions2008-11-17Not applicableUs
Trazodone HydrochlorideTablet50 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2011-01-20Not applicableUs
Trazodone HydrochlorideTablet100 mg/1OralUnit Dose Services2011-01-20Not applicableUs
Trazodone HydrochlorideTablet100 mg/1OralCardinal Health2011-01-202016-03-11Us
Trazodone HydrochlorideTablet100 mg/1OralApotex Corp2008-11-17Not applicableUs
Trazodone HydrochlorideTablet100 mg/1OralContract Pharmacy Services Pa2010-03-09Not applicableUs
Trazodone HydrochlorideTablet50 mg/1OralRebel Distributors Corp.1987-12-11Not applicableUs
Trazodone HydrochlorideTablet50 mg/1OralCarilion Materials Management1990-09-30Not applicableUs
Trazodone HydrochlorideTablet50 mg/1OralDispensing Solutions, Inc.2011-01-20Not applicableUs
Trazodone HydrochlorideTablet50 mg/1OralGolden State Medical Supply, Inc.2008-11-17Not applicableUs
Trazodone HydrochlorideTablet50 mg/1OralMed Vantx, Inc.2011-01-20Not applicableUs
Trazodone HydrochlorideTablet150 mg/1OralAvera Mc Kennan Hospital2015-04-17Not applicableUs
Trazodone HydrochlorideTablet150 mg/1OralREMEDYREPACK INC.2010-10-262016-10-13Us
Trazodone HydrochlorideTablet300 mg/1OralAv Kare, Inc.2014-02-06Not applicableUs
Trazodone HydrochlorideTablet150 mg/1OralA S Medication Solutions1990-09-30Not applicableUs
Trazodone HydrochlorideTablet150 mg/1OralDIRECT RX2014-01-01Not applicableUs
Trazodone HydrochlorideTablet300 mg/1OralTorrent Pharmaceuticals Limited2013-11-27Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
BeneficatNot Available
DepraxNot Available
DesirelNot Available
DesyrelBristol-Myers Squibb
Desyrel DividoseBristol-Myers Squibb
MesyrelNot Available
MolipaxinNot Available
ThombranNot Available
TrialodineNot Available
TritticoNot Available
Brand mixtures
NameLabellerIngredients
TrazaminePhysician Therapeutics Llc
Salts
Name/CASStructureProperties
Trazodone Hydrochloride
25332-39-2
Thumb
  • InChI Key: OHHDIOKRWWOXMT-UHFFFAOYSA-N
  • Monoisotopic Mass: 407.127965797
  • Average Mass: 408.325
DBSALT000344
Categories
UNIIYBK48BXK30
CAS number19794-93-5
WeightAverage: 371.864
Monoisotopic: 371.151288058
Chemical FormulaC19H22ClN5O
InChI KeyPHLBKPHSAVXXEF-UHFFFAOYSA-N
InChI
InChI=1S/C19H22ClN5O/c20-16-5-3-6-17(15-16)23-13-11-22(12-14-23)8-4-10-25-19(26)24-9-2-1-7-18(24)21-25/h1-3,5-7,9,15H,4,8,10-14H2
IUPAC Name
2-{3-[4-(3-chlorophenyl)piperazin-1-yl]propyl}-2H,3H-[1,2,4]triazolo[4,3-a]pyridin-3-one
SMILES
ClC1=CC=CC(=C1)N1CCN(CCCN2N=C3C=CC=CN3C2=O)CC1
Pharmacology
IndicationFor the treatment of depression.
Structured Indications
PharmacodynamicsTrazodone is an antidepressant and hypnotic chemically unrelated to tricyclic, tetracyclic, or other known antidepressant agents. The mechanism of trazodone's antidepressant action in man is not fully understood. In animals, trazodone selectively inhibits serotonin uptake by brain synaptosomes and potentiates the behavioral changes induced by the serotonin precursor, 5-hydroxytryptophan. Cardiac conduction effects of trazodone in the anesthetized dog are qualitatively dissimilar and quantitatively less pronounced than those seen with tricyclic antidepressants. Trazodone is not a monoamine oxidase inhibitor and, unlike amphetamine-type drugs, does not stimulate the central nervous system. In man, trazodone is well absorbed after oral administration without selective localization in any tissue. Since the clearance of trazodone from the body is sufficiently variable, in some patients trazodone may accumulate in the plasma.
Mechanism of actionTrazodone binds at 5-HT2 receptor, it acts as a serotonin agonist at high doses and a serotonin antagonist at low doses. Like fluoxetine, trazodone's antidepressant activity likely results from blockage of serotonin reuptake by inhibiting serotonin reuptake pump at the presynaptic neuronal membrane. If used for long time periods, postsynaptic neuronal receptor binding sites may also be affected. The sedative effect of trazodone is likely the result of alpha-adrenergic blocking action and modest histamine blockade at H1 receptor. It weakly blocks presynaptic alpha2-adrenergic receptors and strongly inhibits postsynaptic alpha1 receptors. Trazodone does not affect the reuptake of norepinephrine or dopamine within the CNS.
TargetKindPharmacological actionActionsOrganismUniProt ID
5-hydroxytryptamine receptor 2AProteinyes
antagonist
HumanP28223 details
5-hydroxytryptamine receptor 2CProteinyes
agonist
HumanP28335 details
Sodium-dependent serotonin transporterProteinyes
inhibitor
HumanP31645 details
5-hydroxytryptamine receptor 1AProteinyes
partial agonist
HumanP08908 details
Histamine H1 receptorProteinunknown
antagonist
HumanP35367 details
Alpha-1A adrenergic receptorProteinno
antagonist
HumanP35348 details
Alpha-2A adrenergic receptorProteinno
antagonist
HumanP08913 details
Related Articles
AbsorptionRapidly and almost completely absorbed following oral administration. Food may decrease the rate and extent of absorption.
Volume of distributionNot Available
Protein binding89-95% bound to plasma proteins in vitro
Metabolism

Undergoes extensive hepatic metabolism via hydroxylation, N-dealkylation, N-oxidation and splitting of the pyridine ring. Cytochrome P450 (CYP) 3A4 catalyzes the formation of the major active metabolite, m-chlorophenylpiperazine (m-CPP). Metabolites may be further conjugated to glucuonic acid or glutathione. CYP2D6 is responsible for 4'-hydroxylation of m-CPP and the formation of at least one glutathione conjugates of m-CPP, a quinone imine-sulhydryl adduct. Oxotriazolopyridinpropionic acid, an inactive metabolite, and its conjugates account for about 20% of the total excreted oral dose. Less than 1% of the oral dose is excreted unchanged. Approximately 70-75% of the dose is eliminated in urine with the remainder being excreted in feces via biliary elimination.

SubstrateEnzymesProduct
Trazodone
4'-hydroxytrazodone glutathione Details
Trazodone
m-chlorophenylpiperazine (m-CPP) Details
Trazodone
triazolopropionic acidDetails
Trazodone
triazolopyridinone epoxideDetails
Trazodone
4'-hydroxytrazodone Details
Trazodone
Not Available
GlutathioneDetails
Trazodone
Not Available
Glucuonic acidDetails
Trazodone
Not Available
Oxotriazolopyridinpropionic acidDetails
Route of eliminationNot Available
Half lifeUndergoes biphasic elimination with an initial phase t1/2 α of 3-6 hours and a terminal phase t1/2 β of 5-9 hours.
ClearanceNot Available
ToxicityLD50=96mg/kg (i.v. in mice)
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 TetrafluoroethaneThe risk or severity of adverse effects can be increased when Trazodone is combined with 1,1,1,2 Tetrafluoroethane.Investigational
7-NitroindazoleThe risk or severity of adverse effects can be increased when Trazodone is combined with 7-Nitroindazole.Experimental
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINEThe risk or severity of adverse effects can be increased when 7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE is combined with Trazodone.Experimental
AbirateroneThe serum concentration of Trazodone can be increased when it is combined with Abiraterone.Approved
AcebutololThe serum concentration of Acebutolol can be decreased when it is combined with Trazodone.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Trazodone.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Trazodone is combined with Aceprometazine.Approved
AcetaminophenThe serum concentration of Acetaminophen can be decreased when it is combined with Trazodone.Approved
AcetophenazineThe risk or severity of adverse effects can be increased when Trazodone is combined with Acetophenazine.Approved
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be decreased when it is combined with Trazodone.Approved, Vet Approved
adipiplonThe risk or severity of adverse effects can be increased when Trazodone is combined with adipiplon.Investigational
AfatinibThe serum concentration of Afatinib can be decreased when it is combined with Trazodone.Approved
AgomelatineThe risk or severity of adverse effects can be increased when Trazodone is combined with Agomelatine.Approved, Investigational
AldosteroneThe serum concentration of Aldosterone can be decreased when it is combined with Trazodone.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Trazodone is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Trazodone is combined with Alfentanil.Approved, Illicit
AlimemazineThe risk or severity of adverse effects can be increased when Alimemazine is combined with Trazodone.Approved, Vet Approved
AlitretinoinThe serum concentration of Alitretinoin can be decreased when it is combined with Trazodone.Approved, Investigational
AlmotriptanThe risk or severity of adverse effects can be increased when Trazodone is combined with Almotriptan.Approved, Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Trazodone is combined with Alphacetylmethadol.Experimental, Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Trazodone.Approved, Illicit, Investigational
AmbrisentanThe serum concentration of Ambrisentan can be decreased when it is combined with Trazodone.Approved, Investigational
AmiodaroneThe metabolism of Trazodone can be decreased when combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Trazodone is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Trazodone.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Trazodone is combined with Amobarbital.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Trazodone.Approved
AmperozideThe risk or severity of adverse effects can be increased when Trazodone is combined with Amperozide.Experimental
AnagrelideTrazodone may increase the QTc-prolonging activities of Anagrelide.Approved
ApixabanThe serum concentration of Apixaban can be decreased when it is combined with Trazodone.Approved
AprepitantThe serum concentration of Trazodone can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Trazodone is combined with Aripiprazole.Approved, Investigational
Arsenic trioxideTrazodone may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
ArtemetherTrazodone may increase the QTc-prolonging activities of Artemether.Approved
ArticaineThe risk or severity of adverse effects can be increased when Trazodone is combined with Articaine.Approved
AsenapineTrazodone may increase the QTc-prolonging activities of Asenapine.Approved
AtazanavirThe serum concentration of Trazodone can be increased when it is combined with Atazanavir.Approved, Investigational
AtenololThe serum concentration of Atenolol can be decreased when it is combined with Trazodone.Approved
AtomoxetineThe metabolism of Trazodone can be decreased when combined with Atomoxetine.Approved
AxitinibThe serum concentration of Axitinib can be decreased when it is combined with Trazodone.Approved, Investigational
AzaperoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Azaperone.Vet Approved
AzelastineTrazodone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Trazodone is combined with Azelastine.Approved
AzithromycinTrazodone may increase the QTc-prolonging activities of Azithromycin.Approved
BaclofenThe risk or severity of adverse effects can be increased when Trazodone is combined with Baclofen.Approved
BarbitalThe risk or severity of adverse effects can be increased when Trazodone is combined with Barbital.Illicit
BedaquilineTrazodone may increase the QTc-prolonging activities of Bedaquiline.Approved
BenmoxinThe risk or severity of adverse effects can be increased when Benmoxin is combined with Trazodone.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Trazodone is combined with Benperidol.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Trazodone is combined with Benzocaine.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Trazodone is combined with Benzyl alcohol.Approved
BetamethasoneThe serum concentration of Betamethasone can be decreased when it is combined with Trazodone.Approved, Vet Approved
BetaxololThe metabolism of Trazodone can be decreased when combined with Betaxolol.Approved
BexaroteneThe serum concentration of Trazodone can be decreased when it is combined with Bexarotene.Approved, Investigational
BifeprunoxThe risk or severity of adverse effects can be increased when Trazodone is combined with Bifeprunox.Investigational
BL-1020The risk or severity of adverse effects can be increased when BL-1020 is combined with Trazodone.Investigational
BoceprevirThe serum concentration of Trazodone can be increased when it is combined with Boceprevir.Approved
BortezomibThe metabolism of Trazodone can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Trazodone can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be decreased when it is combined with Trazodone.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Trazodone.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Trazodone is combined with Brexpiprazole.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Trazodone is combined with Brimonidine.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Trazodone.Approved
BromazepamThe risk or severity of adverse effects can be increased when Trazodone is combined with Bromazepam.Approved, Illicit
BromocriptineThe risk or severity of adverse effects can be increased when Trazodone is combined with Bromocriptine.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Trazodone is combined with Bromperidol.Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Trazodone is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Trazodone is combined with Brotizolam.Approved, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Trazodone.Approved, Investigational
BuprenorphineTrazodone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Trazodone can be decreased when combined with Bupropion.Approved
BuspironeBuspirone may increase the serotonergic activities of Trazodone.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Trazodone.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Trazodone is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Trazodone is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Trazodone is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Trazodone is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Trazodone.Approved, Illicit, Vet Approved
CabazitaxelThe serum concentration of Cabazitaxel can be decreased when it is combined with Trazodone.Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Trazodone.Approved
CaffeineThe serum concentration of Caffeine can be decreased when it is combined with Trazodone.Approved
CamptothecinThe serum concentration of Camptothecin can be decreased when it is combined with Trazodone.Experimental
CanagliflozinThe serum concentration of Canagliflozin can be decreased when it is combined with Trazodone.Approved
CarbamazepineThe metabolism of Trazodone can be increased when combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Trazodone is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Trazodone is combined with Carfentanil.Illicit, Vet Approved
CarfilzomibThe serum concentration of Carfilzomib can be decreased when it is combined with Trazodone.Approved
CariprazineThe risk or severity of adverse effects can be increased when Trazodone is combined with Cariprazine.Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Trazodone is combined with Carisoprodol.Approved
CaroxazoneThe risk or severity of adverse effects can be increased when Caroxazone is combined with Trazodone.Withdrawn
CelecoxibThe metabolism of Trazodone can be decreased when combined with Celecoxib.Approved, Investigational
CeritinibThe serum concentration of Trazodone can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be decreased when it is combined with Trazodone.Withdrawn
CetirizineThe risk or severity of adverse effects can be increased when Trazodone is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Trazodone is combined with Chloral hydrate.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Trazodone.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Chlormezanone.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Trazodone is combined with Chloroprocaine.Approved
ChloroquineTrazodone may increase the QTc-prolonging activities of Chloroquine.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Trazodone is combined with Chlorphenamine.Approved
ChlorpromazineTrazodone may increase the QTc-prolonging activities of Chlorpromazine.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Trazodone is combined with Chlorprothixene.Approved, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Chlorzoxazone.Approved
CholecalciferolThe metabolism of Trazodone can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CimetidineThe serum concentration of Cimetidine can be decreased when it is combined with Trazodone.Approved
CinacalcetThe metabolism of Trazodone can be decreased when combined with Cinacalcet.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Trazodone.Approved, Vet Approved
CiprofloxacinTrazodone may increase the QTc-prolonging activities of Ciprofloxacin.Approved, Investigational
CisaprideTrazodone may increase the QTc-prolonging activities of Cisapride.Approved, Investigational, Withdrawn
CisplatinThe serum concentration of Cisplatin can be decreased when it is combined with Trazodone.Approved
CitalopramTrazodone may increase the QTc-prolonging activities of Citalopram.Approved
ClarithromycinThe metabolism of Trazodone can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Trazodone can be decreased when combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Trazodone is combined with Clidinium.Approved
ClobazamThe serum concentration of Clobazam can be decreased when it is combined with Trazodone.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Trazodone is combined with clomethiazole.Investigational
ClomifeneThe serum concentration of Clomifene can be decreased when it is combined with Trazodone.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Trazodone is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Trazodone is combined with Clonazepam.Approved, Illicit
ClonidineThe serum concentration of Clonidine can be decreased when it is combined with Trazodone.Approved
ClopidogrelThe serum concentration of Clopidogrel can be decreased when it is combined with Trazodone.Approved, Nutraceutical
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Trazodone.Approved, Illicit
ClotrimazoleThe metabolism of Trazodone can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineTrazodone may increase the QTc-prolonging activities of Clozapine.Approved
CobicistatThe serum concentration of Trazodone can be increased when it is combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be decreased when it is combined with Trazodone.Approved
CocaineThe metabolism of Trazodone can be decreased when combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Trazodone.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be decreased when it is combined with Trazodone.Approved
ConivaptanThe serum concentration of Trazodone can be increased when it is combined with Conivaptan.Approved, Investigational
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be decreased when it is combined with Trazodone.Approved
CrizotinibTrazodone may increase the QTc-prolonging activities of Crizotinib.Approved
CyamemazineThe risk or severity of adverse effects can be increased when Trazodone is combined with Cyamemazine.Approved
CyclizineThe risk or severity of adverse effects can be increased when Trazodone is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Trazodone is combined with Cyclobenzaprine.Approved
CyclosporineThe metabolism of Trazodone can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Trazodone is combined with Cyproheptadine.Approved
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Trazodone.Approved
DabrafenibThe serum concentration of Trazodone can be decreased when it is combined with Dabrafenib.Approved
DactinomycinThe serum concentration of Dactinomycin can be decreased when it is combined with Trazodone.Approved
DantroleneThe risk or severity of adverse effects can be increased when Trazodone is combined with Dantrolene.Approved
DapagliflozinThe serum concentration of Dapagliflozin can be decreased when it is combined with Trazodone.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Trazodone.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Trazodone.Investigational
DarifenacinThe metabolism of Trazodone can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Trazodone can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Trazodone can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe serum concentration of Daunorubicin can be decreased when it is combined with Trazodone.Approved
DebrisoquinThe serum concentration of Debrisoquin can be decreased when it is combined with Trazodone.Approved
DeferasiroxThe serum concentration of Trazodone can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Trazodone can be decreased when combined with Delavirdine.Approved
deramciclaneThe risk or severity of adverse effects can be increased when Trazodone is combined with deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Trazodone is combined with Desflurane.Approved
DesipramineThe risk or severity of adverse effects can be increased when Trazodone is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Trazodone is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Trazodone is combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Trazodone is combined with Detomidine.Vet Approved
DexamethasoneThe serum concentration of Trazodone can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Trazodone is combined with Dexbrompheniramine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Trazodone.Approved, Vet Approved
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Trazodone.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Trazodone is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Trazodone.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Trazodone is combined with Dezocine.Approved
DiazepamThe serum concentration of Diazepam can be decreased when it is combined with Trazodone.Approved, Illicit, Vet Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Trazodone.Approved
DifenoxinThe risk or severity of adverse effects can be increased when Trazodone is combined with Difenoxin.Approved, Illicit
DigitoxinThe serum concentration of Digitoxin can be decreased when it is combined with Trazodone.Approved
DigoxinThe serum concentration of Digoxin can be decreased when it is combined with Trazodone.Approved
DihydrocodeineThe risk or severity of adverse effects can be increased when Trazodone is combined with Dihydrocodeine.Approved, Illicit
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Trazodone.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Trazodone is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Trazodone is combined with Dihydromorphine.Experimental, Illicit
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be decreased when it is combined with Trazodone.Illicit
DiltiazemThe metabolism of Trazodone can be decreased when combined with Diltiazem.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Trazodone is combined with Dimenhydrinate.Approved
DiphenhydramineThe metabolism of Trazodone can be decreased when combined with Diphenhydramine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Trazodone is combined with Diphenoxylate.Approved, Illicit
DipyridamoleThe serum concentration of Dipyridamole can be decreased when it is combined with Trazodone.Approved
DisopyramideTrazodone may increase the QTc-prolonging activities of Disopyramide.Approved
DocetaxelThe serum concentration of Docetaxel can be decreased when it is combined with Trazodone.Approved, Investigational
DofetilideTrazodone may increase the QTc-prolonging activities of Dofetilide.Approved
DolasetronTrazodone may increase the QTc-prolonging activities of Dolasetron.Approved
DomperidoneTrazodone may increase the QTc-prolonging activities of Domperidone.Approved, Investigational, Vet Approved
DoramectinThe risk or severity of adverse effects can be increased when Trazodone is combined with Doramectin.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when Trazodone is combined with Doxepin.Approved
DoxorubicinThe serum concentration of Doxorubicin can be decreased when it is combined with Trazodone.Approved, Investigational
DoxycyclineThe metabolism of Trazodone can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Trazodone.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Trazodone is combined with DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Trazodone.Approved, Illicit
DronedaroneTrazodone may increase the QTc-prolonging activities of Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Trazodone.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Trazodone is combined with Drotebanol.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Trazodone.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Trazodone.Approved
EcgonineThe risk or severity of adverse effects can be increased when Trazodone is combined with Ecgonine.Experimental, Illicit
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Trazodone is combined with ECGONINE METHYL ESTER.Experimental
EcopipamThe risk or severity of adverse effects can be increased when Trazodone is combined with Ecopipam.Investigational
EdoxabanThe serum concentration of Edoxaban can be decreased when it is combined with Trazodone.Approved
EfavirenzThe serum concentration of Trazodone can be decreased when it is combined with Efavirenz.Approved, Investigational
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Trazodone.Approved, Investigational
EliglustatTrazodone may increase the QTc-prolonging activities of Eliglustat.Approved
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Trazodone.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Trazodone is combined with Entacapone.Approved, Investigational
EnzalutamideThe serum concentration of Trazodone can be decreased when it is combined with Enzalutamide.Approved
EpinastineThe serum concentration of Epinastine can be decreased when it is combined with Trazodone.Approved, Investigational
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Trazodone is combined with Ergoloid mesylate.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Trazodone is combined with Ergonovine.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Trazodone is combined with Ergotamine.Approved
ErlotinibThe serum concentration of Erlotinib can be decreased when it is combined with Trazodone.Approved, Investigational
ErythromycinTrazodone may increase the QTc-prolonging activities of Erythromycin.Approved, Vet Approved
EscitalopramTrazodone may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe serum concentration of Trazodone can be decreased when it is combined with Eslicarbazepine acetate.Approved
EstazolamThe risk or severity of adverse effects can be increased when Trazodone is combined with Estazolam.Approved, Illicit
EstradiolThe serum concentration of Estradiol can be decreased when it is combined with Trazodone.Approved, Investigational, Vet Approved
EstriolThe serum concentration of Estriol can be decreased when it is combined with Trazodone.Approved, Vet Approved
EstroneThe serum concentration of Estrone can be decreased when it is combined with Trazodone.Approved
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Trazodone.Approved
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Trazodone.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Trazodone.Approved, Illicit, Withdrawn
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Trazodone.Approved
EthosuximideThe risk or severity of adverse effects can be increased when Trazodone is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Trazodone is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Trazodone is combined with Ethyl carbamate.Withdrawn
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Trazodone is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Trazodone is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Trazodone is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Trazodone is combined with Etifoxine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Trazodone is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Trazodone.Approved
EtoperidoneEtoperidone may increase the serotonergic activities of Trazodone.Approved
EtoposideThe serum concentration of Etoposide can be decreased when it is combined with Trazodone.Approved
EtorphineThe risk or severity of adverse effects can be increased when Trazodone is combined with Etorphine.Illicit, Vet Approved
EtravirineThe serum concentration of Trazodone can be decreased when it is combined with Etravirine.Approved
EzetimibeThe serum concentration of Ezetimibe can be decreased when it is combined with Trazodone.Approved
EzogabineThe risk or severity of adverse effects can be increased when Trazodone is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Trazodone is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Trazodone is combined with Fencamfamine.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Trazodone is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of Fesoterodine can be decreased when it is combined with Trazodone.Approved
FexofenadineThe serum concentration of Fexofenadine can be decreased when it is combined with Trazodone.Approved
FidaxomicinThe serum concentration of Fidaxomicin can be decreased when it is combined with Trazodone.Approved
FlecainideTrazodone may increase the QTc-prolonging activities of Flecainide.Approved, Withdrawn
FlibanserinThe risk or severity of adverse effects can be increased when Trazodone is combined with Flibanserin.Approved
FluconazoleThe metabolism of Trazodone can be decreased when combined with Fluconazole.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Trazodone is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Trazodone is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Trazodone is combined with Flunitrazepam.Approved, Illicit
FluoxetineTrazodone may increase the QTc-prolonging activities of Fluoxetine.Approved, Vet Approved
FlupentixolTrazodone may increase the QTc-prolonging activities of Flupentixol.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Trazodone.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Trazodone is combined with Flurazepam.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Trazodone is combined with Fluspirilene.Approved
Fluticasone furoateThe serum concentration of Fluticasone furoate can be decreased when it is combined with Trazodone.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Trazodone is combined with Fluticasone Propionate.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Trazodone.Approved, Investigational
FosamprenavirThe serum concentration of Trazodone can be increased when it is combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Trazodone can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe serum concentration of Trazodone can be decreased when it is combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Trazodone is combined with Fospropofol.Approved, Illicit
FrovatriptanThe risk or severity of adverse effects can be increased when Trazodone is combined with Frovatriptan.Approved, Investigational
FurazolidoneThe risk or severity of adverse effects can be increased when Furazolidone is combined with Trazodone.Approved, Vet Approved
Fusidic AcidThe serum concentration of Trazodone can be increased when it is combined with Fusidic Acid.Approved
GabapentinThe risk or severity of adverse effects can be increased when Trazodone is combined with Gabapentin.Approved, Investigational
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Trazodone is combined with gabapentin enacarbil.Approved
Gadobenic acidTrazodone may increase the QTc-prolonging activities of Gadobenic acid.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Trazodone is combined with Gamma Hydroxybutyric Acid.Approved, Illicit
GefitinibThe serum concentration of Gefitinib can be decreased when it is combined with Trazodone.Approved, Investigational
GemcitabineThe serum concentration of Gemcitabine can be decreased when it is combined with Trazodone.Approved
GemifloxacinTrazodone may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational
GepironeThe risk or severity of adverse effects can be increased when Trazodone is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Trazodone is combined with Glutethimide.Approved, Illicit
GoserelinTrazodone may increase the QTc-prolonging activities of Goserelin.Approved
GranisetronTrazodone may increase the QTc-prolonging activities of Granisetron.Approved, Investigational
GrazoprevirThe serum concentration of Grazoprevir can be decreased when it is combined with Trazodone.Approved
GrepafloxacinThe serum concentration of Grepafloxacin can be decreased when it is combined with Trazodone.Withdrawn
GuanfacineThe risk or severity of adverse effects can be increased when Trazodone is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Trazodone is combined with Halazepam.Approved, Illicit, Withdrawn
HaloperidolTrazodone may increase the QTc-prolonging activities of Haloperidol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Trazodone is combined with Halothane.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Trazodone is combined with Heroin.Approved, Illicit
HexobarbitalThe risk or severity of adverse effects can be increased when Trazodone is combined with Hexobarbital.Approved
HydracarbazineThe risk or severity of adverse effects can be increased when Hydracarbazine is combined with Trazodone.Approved
HydrocodoneTrazodone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydrocortisoneThe serum concentration of Hydrocortisone can be decreased when it is combined with Trazodone.Approved, Vet Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Trazodone.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Trazodone.Approved
IbuprofenThe serum concentration of Ibuprofen can be decreased when it is combined with Trazodone.Approved
IbutilideTrazodone may increase the QTc-prolonging activities of Ibutilide.Approved
IdelalisibThe serum concentration of Trazodone can be increased when it is combined with Idelalisib.Approved
IloperidoneTrazodone may increase the QTc-prolonging activities of Iloperidone.Approved
ImatinibThe metabolism of Trazodone can be decreased when combined with Imatinib.Approved
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Trazodone.Approved
IndacaterolThe serum concentration of Indacaterol can be decreased when it is combined with Trazodone.Approved
IndalpineIndalpine may increase the serotonergic activities of Trazodone.Investigational, Withdrawn
IndinavirThe serum concentration of Trazodone can be increased when it is combined with Indinavir.Approved
IndomethacinThe serum concentration of Indomethacin can be decreased when it is combined with Trazodone.Approved, Investigational
IproclozideThe risk or severity of adverse effects can be increased when Iproclozide is combined with Trazodone.Withdrawn
IproniazidThe risk or severity of adverse effects can be increased when Iproniazid is combined with Trazodone.Withdrawn
IrinotecanThe serum concentration of Irinotecan can be decreased when it is combined with Trazodone.Approved, Investigational
IsavuconazoniumThe metabolism of Trazodone can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Trazodone.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Trazodone is combined with Isoflurane.Approved, Vet Approved
IsoniazidThe metabolism of Trazodone can be decreased when combined with Isoniazid.Approved
IsradipineThe metabolism of Trazodone can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Trazodone can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Trazodone can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Ivermectin can be decreased when it is combined with Trazodone.Approved, Vet Approved
KetamineThe risk or severity of adverse effects can be increased when Trazodone is combined with Ketamine.Approved, Vet Approved
KetazolamThe serum concentration of Ketazolam can be decreased when it is combined with Trazodone.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Ketobemidone.Approved
KetoconazoleThe metabolism of Trazodone can be decreased when combined with Ketoconazole.Approved, Investigational
LamivudineThe serum concentration of Lamivudine can be decreased when it is combined with Trazodone.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be decreased when it is combined with Trazodone.Approved, Investigational
LansoprazoleThe serum concentration of Lansoprazole can be decreased when it is combined with Trazodone.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be decreased when it is combined with Trazodone.Approved
LenalidomideThe serum concentration of Lenalidomide can be decreased when it is combined with Trazodone.Approved
LenvatinibTrazodone may increase the QTc-prolonging activities of Lenvatinib.Approved
LeuprolideTrazodone may increase the QTc-prolonging activities of Leuprolide.Approved, Investigational
LevetiracetamThe serum concentration of Levetiracetam can be decreased when it is combined with Trazodone.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Trazodone is combined with Levobupivacaine.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Trazodone is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Trazodone is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Trazodone is combined with Levodopa.Approved
LevofloxacinTrazodone may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Trazodone is combined with Levomethadyl Acetate.Approved
LevomilnacipranThe risk or severity of adverse effects can be increased when Trazodone is combined with Levomilnacipran.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Trazodone is combined with Levorphanol.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Trazodone.Approved, Vet Approved
LinagliptinThe serum concentration of Linagliptin can be decreased when it is combined with Trazodone.Approved
LinezolidLinezolid may increase the serotonergic activities of Trazodone.Approved, Investigational
LithiumThe risk or severity of adverse effects can be increased when Trazodone is combined with Lithium.Approved
LofentanilThe risk or severity of adverse effects can be increased when Trazodone is combined with Lofentanil.Illicit
LoperamideThe serum concentration of Loperamide can be decreased when it is combined with Trazodone.Approved
LopinavirLopinavir may increase the QTc-prolonging activities of Trazodone.Approved
LoratadineThe risk or severity of adverse effects can be increased when Trazodone is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Trazodone.Approved
LorcaserinThe risk or severity of adverse effects can be increased when Trazodone is combined with Lorcaserin.Approved
LosartanThe serum concentration of Losartan can be decreased when it is combined with Trazodone.Approved
LovastatinThe metabolism of Trazodone can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Trazodone.Approved
Lu AA21004The risk or severity of adverse effects can be increased when Trazodone is combined with Lu AA21004.Investigational
LuliconazoleThe serum concentration of Trazodone can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Trazodone can be increased when combined with Lumacaftor.Approved
LumefantrineTrazodone may increase the QTc-prolonging activities of Lumefantrine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Lurasidone.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Trazodone.Approved, Vet Approved
MannitolThe serum concentration of Mannitol can be decreased when it is combined with Trazodone.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Trazodone is combined with Maprotiline.Approved
MebanazineThe risk or severity of adverse effects can be increased when Mebanazine is combined with Trazodone.Withdrawn
MeclizineThe risk or severity of adverse effects can be increased when Trazodone is combined with Meclizine.Approved
MedetomidineThe risk or severity of adverse effects can be increased when Trazodone is combined with Medetomidine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Trazodone is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Melperone.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Trazodone is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Trazodone.Approved, Illicit
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Trazodone.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Trazodone is combined with Metaxalone.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Trazodone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Trazodone is combined with Methadyl Acetate.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Trazodone is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Methaqualone.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Trazodone is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Trazodone.Approved
MethotrexateThe serum concentration of Methotrexate can be decreased when it is combined with Trazodone.Approved
MethotrimeprazineTrazodone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Trazodone is combined with Methoxyflurane.Approved, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Trazodone is combined with Methsuximide.Approved
Methylene blueTrazodone may increase the serotonergic activities of Methylene blue.Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Trazodone is combined with Methylphenobarbital.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be decreased when it is combined with Trazodone.Approved, Vet Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Trazodone is combined with Metoclopramide.Approved, Investigational
MetoprololThe serum concentration of Metoprolol can be decreased when it is combined with Trazodone.Approved, Investigational
MetyrosineTrazodone may increase the sedative activities of Metyrosine.Approved
MidazolamThe serum concentration of Midazolam can be decreased when it is combined with Trazodone.Approved, Illicit
MifepristoneMifepristone may increase the QTc-prolonging activities of Trazodone.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Trazodone is combined with Milnacipran.Approved
MinaprineThe risk or severity of adverse effects can be increased when Minaprine is combined with Trazodone.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Trazodone.Approved, Investigational
MirabegronThe serum concentration of Mirabegron can be decreased when it is combined with Trazodone.Approved
MirtazapineTrazodone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitotaneThe serum concentration of Trazodone can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Mitoxantrone can be decreased when it is combined with Trazodone.Approved, Investigational
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Trazodone.Approved
ModafinilThe serum concentration of Trazodone can be decreased when it is combined with Modafinil.Approved, Investigational
MolindoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Molindone.Approved
MoricizineThe risk or severity of adverse effects can be increased when Moricizine is combined with Trazodone.Approved, Withdrawn
MorphineThe serum concentration of Morphine can be decreased when it is combined with Trazodone.Approved, Investigational
MoxifloxacinTrazodone may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Trazodone.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Trazodone.Approved, Investigational
NadololThe serum concentration of Nadolol can be decreased when it is combined with Trazodone.Approved
NafcillinThe serum concentration of Trazodone can be decreased when it is combined with Nafcillin.Approved
NalbuphineThe risk or severity of adverse effects can be increased when Trazodone is combined with Nalbuphine.Approved
NaloxoneThe serum concentration of Naloxone can be decreased when it is combined with Trazodone.Approved, Vet Approved
NaratriptanThe risk or severity of adverse effects can be increased when Trazodone is combined with Naratriptan.Approved, Investigational
NefazodoneThe metabolism of Trazodone can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Trazodone can be increased when it is combined with Nelfinavir.Approved
NetupitantThe serum concentration of Trazodone can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Trazodone can be increased when combined with Nevirapine.Approved
NialamideThe risk or severity of adverse effects can be increased when Nialamide is combined with Trazodone.Withdrawn
NicardipineThe serum concentration of Nicardipine can be decreased when it is combined with Trazodone.Approved
NifedipineThe serum concentration of Nifedipine can be decreased when it is combined with Trazodone.Approved
NilotinibTrazodone may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
NintedanibThe serum concentration of Nintedanib can be decreased when it is combined with Trazodone.Approved
NitrazepamThe risk or severity of adverse effects can be increased when Trazodone is combined with Nitrazepam.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Trazodone is combined with Nitrous oxide.Approved, Vet Approved
NizatidineThe serum concentration of Nizatidine can be decreased when it is combined with Trazodone.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Trazodone.Approved
OctamoxinThe risk or severity of adverse effects can be increased when Octamoxin is combined with Trazodone.Withdrawn
OfloxacinTrazodone may increase the QTc-prolonging activities of Ofloxacin.Approved
OlanzapineThe serum concentration of Olanzapine can be decreased when it is combined with Trazodone.Approved, Investigational
OlaparibThe metabolism of Trazodone can be decreased when combined with Olaparib.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Trazodone is combined with Olopatadine.Approved
OmbitasvirThe serum concentration of Ombitasvir can be decreased when it is combined with Trazodone.Approved
OndansetronTrazodone may increase the QTc-prolonging activities of Ondansetron.Approved
OpiumThe risk or severity of adverse effects can be increased when Trazodone is combined with Opium.Approved, Illicit
OrphenadrineTrazodone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Trazodone is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Trazodone can be increased when it is combined with Osimertinib.Approved
OxazepamThe risk or severity of adverse effects can be increased when Trazodone is combined with Oxazepam.Approved
OxetacaineThe risk or severity of adverse effects can be increased when Trazodone is combined with Oxetacaine.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Trazodone is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Trazodone is combined with Oxybuprocaine.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Trazodone.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Oxymorphone.Approved, Investigational, Vet Approved
PaclitaxelThe serum concentration of Paclitaxel can be decreased when it is combined with Trazodone.Approved, Vet Approved
PalbociclibThe serum concentration of Trazodone can be increased when it is combined with Palbociclib.Approved
PaliperidoneTrazodone may increase the QTc-prolonging activities of Paliperidone.Approved
PalonosetronPalonosetron may increase the serotonergic activities of Trazodone.Approved, Investigational
PanobinostatThe serum concentration of Trazodone can be increased when it is combined with Panobinostat.Approved, Investigational
ParaldehydeTrazodone may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
PargylineThe risk or severity of adverse effects can be increased when Pargyline is combined with Trazodone.Approved
ParoxetineThe metabolism of Trazodone can be decreased when combined with Paroxetine.Approved, Investigational
PazopanibTrazodone may increase the QTc-prolonging activities of Pazopanib.Approved
Peginterferon alfa-2bThe serum concentration of Trazodone can be decreased when it is combined with Peginterferon alfa-2b.Approved
PentamidineTrazodone may increase the QTc-prolonging activities of Pentamidine.Approved
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Trazodone.Approved, Vet Approved
PentobarbitalThe metabolism of Trazodone can be increased when combined with Pentobarbital.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Trazodone.Approved
PerazineThe risk or severity of adverse effects can be increased when Perazine is combined with Trazodone.Investigational
PerflutrenTrazodone may increase the QTc-prolonging activities of Perflutren.Approved
PerospironeThe risk or severity of adverse effects can be increased when Trazodone is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Trazodone.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Trazodone.Approved
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Trazodone.Approved
PheniprazineThe risk or severity of adverse effects can be increased when Pheniprazine is combined with Trazodone.Withdrawn
PhenobarbitalThe metabolism of Trazodone can be increased when combined with Phenobarbital.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Trazodone is combined with Phenoxyethanol.Approved
PhenoxypropazineThe risk or severity of adverse effects can be increased when Phenoxypropazine is combined with Trazodone.Withdrawn
PhenytoinThe serum concentration of Trazodone can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PimozideTrazodone may increase the QTc-prolonging activities of Pimozide.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Pipamperone.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Trazodone is combined with Pipotiazine.Approved
PiritramideThe risk or severity of adverse effects can be increased when Trazodone is combined with Piritramide.Investigational
PirlindoleThe risk or severity of adverse effects can be increased when Pirlindole is combined with Trazodone.Approved
PitavastatinThe serum concentration of Pitavastatin can be decreased when it is combined with Trazodone.Approved
PivhydrazineThe risk or severity of adverse effects can be increased when Pivhydrazine is combined with Trazodone.Withdrawn
PizotifenThe risk or severity of adverse effects can be increased when Trazodone is combined with Pizotifen.Approved
PomalidomideThe serum concentration of Pomalidomide can be decreased when it is combined with Trazodone.Approved
PonatinibThe serum concentration of Ponatinib can be decreased when it is combined with Trazodone.Approved
PosaconazoleThe metabolism of Trazodone can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PramipexoleTrazodone may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Trazodone is combined with Pramocaine.Approved
PravastatinThe serum concentration of Pravastatin can be decreased when it is combined with Trazodone.Approved
PrazepamThe risk or severity of adverse effects can be increased when Trazodone is combined with Prazepam.Approved, Illicit
PrazosinThe serum concentration of Prazosin can be decreased when it is combined with Trazodone.Approved
PrednisoloneThe serum concentration of Prednisolone can be decreased when it is combined with Trazodone.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be decreased when it is combined with Trazodone.Approved, Vet Approved
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Trazodone.Approved, Illicit, Investigational
PregnanoloneThe risk or severity of adverse effects can be increased when Trazodone is combined with Pregnanolone.Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Trazodone is combined with Prilocaine.Approved
PrimaquineTrazodone may increase the QTc-prolonging activities of Primaquine.Approved
PrimidoneThe metabolism of Trazodone can be increased when combined with Primidone.Approved, Vet Approved
ProcainamideTrazodone may increase the QTc-prolonging activities of Procainamide.Approved
ProcaineThe risk or severity of adverse effects can be increased when Trazodone is combined with Procaine.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Trazodone is combined with Procarbazine.Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Trazodone.Approved, Vet Approved
ProgesteroneThe serum concentration of Progesterone can be decreased when it is combined with Trazodone.Approved, Vet Approved
PromazineTrazodone may increase the QTc-prolonging activities of Promazine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Trazodone is combined with Promethazine.Approved
PropafenoneTrazodone may increase the QTc-prolonging activities of Propafenone.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Trazodone is combined with Proparacaine.Approved, Vet Approved
PropericiazineThe risk or severity of adverse effects can be increased when Trazodone is combined with Propericiazine.Approved
PropiopromazineThe risk or severity of adverse effects can be increased when Propiopromazine is combined with Trazodone.Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Trazodone is combined with Propofol.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Trazodone is combined with Propoxycaine.Approved
PropranololThe serum concentration of Propranolol can be decreased when it is combined with Trazodone.Approved, Investigational
ProthipendylThe risk or severity of adverse effects can be increased when Trazodone is combined with Prothipendyl.Investigational
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Trazodone.Approved
PSD502The risk or severity of adverse effects can be increased when Trazodone is combined with PSD502.Investigational
QuazepamThe risk or severity of adverse effects can be increased when Trazodone is combined with Quazepam.Approved, Illicit
QuetiapineTrazodone may increase the QTc-prolonging activities of Quetiapine.Approved
QuinidineTrazodone may increase the QTc-prolonging activities of Quinidine.Approved
QuinineTrazodone may increase the QTc-prolonging activities of Quinine.Approved
RacloprideThe risk or severity of adverse effects can be increased when Trazodone is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Trazodone is combined with Ramelteon.Approved, Investigational
RanitidineThe serum concentration of Ranitidine can be decreased when it is combined with Trazodone.Approved
RanolazineThe metabolism of Trazodone can be decreased when combined with Ranolazine.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Trazodone.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Trazodone is combined with Remifentanil.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Trazodone.Approved, Withdrawn
ReserpineThe serum concentration of Reserpine can be decreased when it is combined with Trazodone.Approved
RifabutinThe metabolism of Trazodone can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Trazodone can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Trazodone can be increased when combined with Rifapentine.Approved
RisperidoneThe serum concentration of Risperidone can be decreased when it is combined with Trazodone.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Trazodone is combined with Ritanserin.Investigational
RitonavirThe serum concentration of Trazodone can be increased when it is combined with Ritonavir.Approved, Investigational
RivaroxabanThe serum concentration of Rivaroxaban can be decreased when it is combined with Trazodone.Approved
RizatriptanThe risk or severity of adverse effects can be increased when Trazodone is combined with Rizatriptan.Approved
RolapitantThe metabolism of Trazodone can be decreased when combined with Rolapitant.Approved
RomidepsinThe serum concentration of Romidepsin can be decreased when it is combined with Trazodone.Approved, Investigational
RomifidineThe risk or severity of adverse effects can be increased when Trazodone is combined with Romifidine.Vet Approved
RopiniroleTrazodone may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Trazodone.Approved
RotigotineTrazodone may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Trazodone.Approved
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Trazodone is combined with S-Ethylisothiourea.Experimental
SafrazineThe risk or severity of adverse effects can be increased when Safrazine is combined with Trazodone.Withdrawn
Sage 547The risk or severity of adverse effects can be increased when Trazodone is combined with Sage 547.Investigational
Salicylic acidThe serum concentration of Salicylic acid can be decreased when it is combined with Trazodone.Approved, Vet Approved
SaquinavirSaquinavir may increase the QTc-prolonging activities of Trazodone.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Trazodone is combined with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Trazodone.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Trazodone.Approved, Investigational, Vet Approved
SelexipagThe serum concentration of Selexipag can be decreased when it is combined with Trazodone.Approved
SertindoleThe risk or severity of adverse effects can be increased when Trazodone is combined with Sertindole.Approved, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Trazodone is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Trazodone is combined with Sevoflurane.Approved, Vet Approved
SildenafilThe metabolism of Trazodone can be decreased when combined with Sildenafil.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be decreased when it is combined with Trazodone.Approved
SiltuximabThe serum concentration of Trazodone can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Trazodone can be increased when it is combined with Simeprevir.Approved
SitagliptinThe serum concentration of Sitagliptin can be decreased when it is combined with Trazodone.Approved, Investigational
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Trazodone.Approved
SofosbuvirThe serum concentration of Sofosbuvir can be decreased when it is combined with Trazodone.Approved
SorafenibThe serum concentration of Sorafenib can be decreased when it is combined with Trazodone.Approved, Investigational
SotalolTrazodone may increase the QTc-prolonging activities of Sotalol.Approved
SparfloxacinThe serum concentration of Sparfloxacin can be decreased when it is combined with Trazodone.Approved
SphingosineThe serum concentration of Sphingosine can be decreased when it is combined with Trazodone.Experimental
St. John's WortThe serum concentration of Trazodone can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Trazodone can be increased when it is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Trazodone is combined with Sufentanil.Approved, Investigational
SulfisoxazoleTrazodone may increase the QTc-prolonging activities of Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Trazodone.Approved
SumatriptanThe risk or severity of adverse effects can be increased when Trazodone is combined with Sumatriptan.Approved, Investigational
SuvorexantTrazodone may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Trazodone.Approved, Investigational
TacrolimusThe serum concentration of Tacrolimus can be decreased when it is combined with Trazodone.Approved, Investigational
TamoxifenThe serum concentration of Tamoxifen can be decreased when it is combined with Trazodone.Approved
TandospironeThe risk or severity of adverse effects can be increased when Trazodone is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Trazodone.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Trazodone is combined with Tasimelteon.Approved
Taurocholic AcidThe serum concentration of Taurocholic Acid can be decreased when it is combined with Trazodone.Experimental
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be decreased when it is combined with Trazodone.Approved
Tedizolid PhosphateTedizolid Phosphate may increase the serotonergic activities of Trazodone.Approved
TelaprevirThe serum concentration of Trazodone can be increased when it is combined with Telaprevir.Approved
TelavancinTrazodone may increase the QTc-prolonging activities of Telavancin.Approved
TelithromycinThe metabolism of Trazodone can be decreased when combined with Telithromycin.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Trazodone.Approved
TemsirolimusThe serum concentration of Temsirolimus can be decreased when it is combined with Trazodone.Approved
TerbinafineThe metabolism of Trazodone can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TetrabenazineTrazodone may increase the QTc-prolonging activities of Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Trazodone is combined with Tetracaine.Approved, Vet Approved
TetrodotoxinThe risk or severity of adverse effects can be increased when Trazodone is combined with Tetrodotoxin.Investigational
ThalidomideTrazodone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Trazodone is combined with Thiamylal.Approved, Vet Approved
ThiethylperazineThe risk or severity of adverse effects can be increased when Thiethylperazine is combined with Trazodone.Withdrawn
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Trazodone.Approved, Vet Approved
ThioproperazineThe risk or severity of adverse effects can be increased when Trazodone is combined with Thioproperazine.Approved
ThioridazineTrazodone may increase the QTc-prolonging activities of Thioridazine.Approved
ThiothixeneThe risk or severity of adverse effects can be increased when Trazodone is combined with Thiothixene.Approved
TiagabineThe risk or severity of adverse effects can be increased when Trazodone is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Trazodone is combined with Tiapride.Investigational
TicagrelorThe serum concentration of Ticagrelor can be decreased when it is combined with Trazodone.Approved
TiclopidineThe metabolism of Trazodone can be decreased when combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Trazodone is combined with Tiletamine.Vet Approved
TimololThe serum concentration of Timolol can be decreased when it is combined with Trazodone.Approved
TipranavirThe serum concentration of Trazodone can be increased when it is combined with Tipranavir.Approved, Investigational
TizanidineThe risk or severity of adverse effects can be increased when Trazodone is combined with Tizanidine.Approved
TocilizumabThe serum concentration of Trazodone can be decreased when it is combined with Tocilizumab.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Trazodone is combined with Tolcapone.Approved, Withdrawn
ToloxatoneThe risk or severity of adverse effects can be increased when Toloxatone is combined with Trazodone.Approved
TolvaptanThe serum concentration of Tolvaptan can be decreased when it is combined with Trazodone.Approved
TopiramateThe risk or severity of adverse effects can be increased when Trazodone is combined with Topiramate.Approved
TopotecanThe serum concentration of Topotecan can be decreased when it is combined with Trazodone.Approved, Investigational
ToremifeneTrazodone may increase the QTc-prolonging activities of Toremifene.Approved, Investigational
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Trazodone.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Trazodone.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Trazodone.Approved
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be decreased when it is combined with Trazodone.Approved
TriazolamThe risk or severity of adverse effects can be increased when Trazodone is combined with Triazolam.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Trazodone.Approved
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Trazodone.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Trazodone is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Trazodone is combined with Triprolidine.Approved
TropisetronTropisetron may increase the serotonergic activities of Trazodone.Investigational
Uc1010The risk or severity of adverse effects can be increased when Trazodone is combined with Uc1010.Investigational
UlipristalThe serum concentration of Ulipristal can be decreased when it is combined with Trazodone.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be decreased when it is combined with Trazodone.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Trazodone.Approved, Investigational
VandetanibTrazodone may increase the QTc-prolonging activities of Vandetanib.Approved
VecuroniumThe serum concentration of Vecuronium can be decreased when it is combined with Trazodone.Approved
VemurafenibTrazodone may increase the QTc-prolonging activities of Vemurafenib.Approved
VenetoclaxThe serum concentration of Venetoclax can be decreased when it is combined with Trazodone.Approved
VenlafaxineVenlafaxine may increase the serotonergic activities of Trazodone.Approved
VerapamilThe metabolism of Trazodone can be decreased when combined with Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Trazodone is combined with Vigabatrin.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Vilazodone.Approved
VinblastineThe serum concentration of Vinblastine can be decreased when it is combined with Trazodone.Approved
VincristineThe serum concentration of Vincristine can be decreased when it is combined with Trazodone.Approved, Investigational
VismodegibThe serum concentration of Vismodegib can be decreased when it is combined with Trazodone.Approved
VoriconazoleThe metabolism of Trazodone can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Trazodone is combined with Vortioxetine.Approved
WarfarinTrazodone may decrease the anticoagulant activities of Warfarin.Approved
XylazineThe risk or severity of adverse effects can be increased when Trazodone is combined with Xylazine.Vet Approved
YohimbineThe therapeutic efficacy of Trazodone can be decreased when used in combination with Yohimbine.Approved, Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Trazodone is combined with Zaleplon.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Trazodone is combined with Ziconotide.Approved
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Trazodone.Approved
ZimelidineZimelidine may increase the serotonergic activities of Trazodone.Withdrawn
ZiprasidoneTrazodone may increase the QTc-prolonging activities of Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Trazodone is combined with Zolazepam.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Trazodone.Approved, Investigational
ZolpidemTrazodone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Trazodone is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Trazodone is combined with Zopiclone.Approved
ZotepineThe risk or severity of adverse effects can be increased when Trazodone is combined with Zotepine.Approved
ZuclopenthixolTrazodone may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
Food Interactions
  • Avoid alcohol.
  • Food decreases the rate and extent of absorption.
References
Synthesis ReferenceNot Available
General References
  1. Marek GJ, McDougle CJ, Price LH, Seiden LS: A comparison of trazodone and fluoxetine: implications for a serotonergic mechanism of antidepressant action. Psychopharmacology (Berl). 1992;109(1-2):2-11. [PubMed:1365657 ]
  2. Jauch R, Kopitar Z, Prox A, Zimmer A: [Pharmacokinetics and metabolism of trazodone in man (author's transl)]. Arzneimittelforschung. 1976;26(11):2084-9. [PubMed:1037253 ]
  3. Rotzinger S, Fang J, Baker GB: Trazodone is metabolized to m-chlorophenylpiperazine by CYP3A4 from human sources. Drug Metab Dispos. 1998 Jun;26(6):572-5. [PubMed:9616194 ]
  4. Kalgutkar AS, Henne KR, Lame ME, Vaz AD, Collin C, Soglia JR, Zhao SX, Hop CE: Metabolic activation of the nontricyclic antidepressant trazodone to electrophilic quinone-imine and epoxide intermediates in human liver microsomes and recombinant P4503A4. Chem Biol Interact. 2005 Jun 30;155(1-2):10-20. Epub 2005 Apr 18. [PubMed:15978881 ]
  5. Otani K, Yasui N, Kaneko S, Ishida M, Ohkubo T, Osanai T, Sugawara K, Fukushima Y: Trazodone treatment increases plasma prolactin concentrations in depressed patients. Int Clin Psychopharmacol. 1995 Jun;10(2):115-7. [PubMed:7673654 ]
  6. Saletu-Zyhlarz GM, Abu-Bakr MH, Anderer P, Gruber G, Mandl M, Strobl R, Gollner D, Prause W, Saletu B: Insomnia in depression: differences in objective and subjective sleep and awakening quality to normal controls and acute effects of trazodone. Prog Neuropsychopharmacol Biol Psychiatry. 2002 Feb;26(2):249-60. [PubMed:11817501 ]
  7. Fink HA, MacDonald R, Rutks IR, Wilt TJ: Trazodone for erectile dysfunction: a systematic review and meta-analysis. BJU Int. 2003 Sep;92(4):441-6. [PubMed:12930437 ]
External Links
ATC CodesN06AX05
AHFS Codes
  • 28:16.04.24
PDB EntriesNot Available
FDA labelDownload (151 KB)
MSDSDownload (73.7 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9829
Caco-2 permeable-0.6166
P-glycoprotein substrateSubstrate0.547
P-glycoprotein inhibitor IInhibitor0.8634
P-glycoprotein inhibitor IIInhibitor0.8889
Renal organic cation transporterInhibitor0.6479
CYP450 2C9 substrateNon-substrate0.7897
CYP450 2D6 substrateSubstrate0.8919
CYP450 3A4 substrateSubstrate0.7408
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.6613
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.83
Ames testNon AMES toxic0.5133
CarcinogenicityNon-carcinogens0.8545
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.7007 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.8994
hERG inhibition (predictor II)Inhibitor0.7503
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Labopharm inc
  • Apothecon inc div bristol myers squibb
  • Alvogen inc
  • American therapeutics inc
  • Apotex inc
  • Matrix laboratories ltd
  • Mutual pharmaceutical co inc
  • Mylan pharmaceuticals inc
  • Pliva inc
  • Quantum pharmics ltd
  • Sandoz inc
  • Teva pharmaceuticals usa inc
  • Usl pharma inc
  • Vintage pharmaceuticals llc
  • Watson laboratories inc
Packagers
Dosage forms
FormRouteStrength
TabletOral150 mg
TabletOral50 mg
TabletOral300 mg
Tablet, extended releaseOral150 mg/1
Tablet, extended releaseOral150 mg
Tablet, extended releaseOral300 mg/1
Tablet, extended releaseOral300 mg
TabletOral100 mg
TabletOral75 mg
Kit
TabletOral100 mg/1
TabletOral150 mg/1
TabletOral300 mg/1
TabletOral50 mg/1
Tablet, film coatedOral100 mg/1
Tablet, film coatedOral150 mg/1
Tablet, film coatedOral50 mg/1
TabletOral68.25 mg
Prices
Unit descriptionCostUnit
Trazodone hcl powder8.26USD g
Desyrel 300 mg tablet6.03USD tablet
TraZODone HCl 300 mg tablet5.65USD tablet
Trazodone 300 mg tablet5.44USD tablet
Desyrel 100 mg tablet4.6USD tablet
Desyrel 150 mg tablet3.39USD tablet
TraZODone HCl 150 mg tablet1.53USD tablet
Trazodone 150 mg tablet1.47USD tablet
Desyrel 50 mg tablet1.33USD tablet
TraZODone HCl 100 mg tablet0.76USD tablet
Trazodone 100 mg tablet0.73USD tablet
Apo-Trazodone D 150 mg Tablet0.61USD tablet
Desyrel Dividose 150 mg Tablet0.61USD tablet
Novo-Trazodone 150 mg Tablet0.61USD tablet
Nu-Trazodone-D 150 mg Tablet0.61USD tablet
Ratio-Trazodone 150 mg Tablet0.61USD tablet
TraZODone HCl 50 mg tablet0.59USD tablet
Trazodone 50 mg tablet0.57USD tablet
Nu-Trazodone 100 mg Tablet0.41USD tablet
Pms-Trazodone 100 mg Tablet0.41USD tablet
Ratio-Trazodone 100 mg Tablet0.41USD tablet
Apo-Trazodone 100 mg Tablet0.41USD tablet
Desyrel 100 mg Tablet0.41USD tablet
Mylan-Trazodone 100 mg Tablet0.41USD tablet
Novo-Trazodone 100 mg Tablet0.41USD tablet
Pms-Trazodone 75 mg Tablet0.34USD tablet
Apo-Trazodone 50 mg Tablet0.23USD tablet
Mylan-Trazodone 50 mg Tablet0.23USD tablet
Novo-Trazodone 50 mg Tablet0.23USD tablet
Nu-Trazodone 50 mg Tablet0.23USD tablet
Pms-Trazodone 50 mg Tablet0.23USD tablet
Ratio-Trazodone 50 mg Tablet0.23USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6607748 No2000-06-292020-06-29Us
US7829120 No2007-03-272027-03-27Us
US8133893 No2009-03-132029-03-13Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point87 °CPhysProp
water solubilitySparigly solubleNot Available
logP2.9Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.29 mg/mLALOGPS
logP2.68ALOGPS
logP3.13ChemAxon
logS-3.1ALOGPS
pKa (Strongest Basic)7.09ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area42.39 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity105.88 m3·mol-1ChemAxon
Polarizability40.12 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-0a4i-7980000000-5d2bde624fdd9a946993View in MoNA
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenylpiperazines. These are compounds containing a phenylpiperazine skeleton, which consists of a piperazine bound to a phenyl group.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassDiazinanes
Sub ClassPiperazines
Direct ParentPhenylpiperazines
Alternative Parents
Substituents
  • N-arylpiperazine
  • Phenylpiperazine
  • Triazolopyridine
  • Substituted aniline
  • Dialkylarylamine
  • N-alkylpiperazine
  • Pyridinone
  • Halobenzene
  • Chlorobenzene
  • Aniline
  • Benzenoid
  • Pyridine
  • Monocyclic benzene moiety
  • Aryl halide
  • Aryl chloride
  • Heteroaromatic compound
  • 1,2,4-triazole
  • Triazole
  • Azole
  • Tertiary aliphatic amine
  • Tertiary amine
  • Azacycle
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Virus receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates...
Gene Name:
HTR2A
Uniprot ID:
P28223
Molecular Weight:
52602.58 Da
References
  1. Pazzagli M, Giovannini MG, Pepeu G: Trazodone increases extracellular serotonin levels in the frontal cortex of rats. Eur J Pharmacol. 1999 Nov 3;383(3):249-57. [PubMed:10594316 ]
  2. Marcoli M, Rosu C, Bonfanti A, Raiteri M, Maura G: Inhibitory presynaptic 5-hydroxytryptamine(2A) receptors regulate evoked glutamate release from rat cerebellar mossy fibers. J Pharmacol Exp Ther. 2001 Dec;299(3):1106-11. [PubMed:11714900 ]
  3. Marek GJ, McDougle CJ, Price LH, Seiden LS: A comparison of trazodone and fluoxetine: implications for a serotonergic mechanism of antidepressant action. Psychopharmacology (Berl). 1992;109(1-2):2-11. [PubMed:1365657 ]
  4. Luparini MR, Garrone B, Pazzagli M, Pinza M, Pepeu G: A cortical GABA-5HT interaction in the mechanism of action of the antidepressant trazodone. Prog Neuropsychopharmacol Biol Psychiatry. 2004 Nov;28(7):1117-27. [PubMed:15610924 ]
  5. Conn PJ, Sanders-Bush E: Relative efficacies of piperazines at the phosphoinositide hydrolysis-linked serotonergic (5-HT-2 and 5-HT-1c) receptors. J Pharmacol Exp Ther. 1987 Aug;242(2):552-7. [PubMed:3039120 ]
  6. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-iodophenyl-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modul...
Gene Name:
HTR2C
Uniprot ID:
P28335
Molecular Weight:
51820.705 Da
References
  1. Fiorella D, Rabin RA, Winter JC: The role of the 5-HT2A and 5-HT2C receptors in the stimulus effects of m-chlorophenylpiperazine. Psychopharmacology (Berl). 1995 May;119(2):222-30. [PubMed:7659770 ]
  2. Conn PJ, Sanders-Bush E: Relative efficacies of piperazines at the phosphoinositide hydrolysis-linked serotonergic (5-HT-2 and 5-HT-1c) receptors. J Pharmacol Exp Ther. 1987 Aug;242(2):552-7. [PubMed:3039120 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Serotonin:sodium symporter activity
Specific Function:
Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into the pre-synaptic terminal for re-utilization. Plays a key role in mediating regulation of the availability of serotonin to other receptors of serotonergic systems. Terminates the action of serotonin an...
Gene Name:
SLC6A4
Uniprot ID:
P31645
Molecular Weight:
70324.165 Da
References
  1. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [PubMed:9537821 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
partial agonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Beta-arrestin family members inhibit signaling via G pro...
Gene Name:
HTR1A
Uniprot ID:
P08908
Molecular Weight:
46106.335 Da
References
  1. Odagaki Y, Toyoshima R, Yamauchi T: Trazodone and its active metabolite m-chlorophenylpiperazine as partial agonists at 5-HT1A receptors assessed by [35S]GTPgammaS binding. J Psychopharmacol. 2005 May;19(3):235-41. [PubMed:15888508 ]
  2. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]
  3. Subhash MN, Srinivas BN, Vinod KY: Alterations in 5-HT(1A) receptors and adenylyl cyclase response by trazodone in regions of rat brain. Life Sci. 2002 Aug 16;71(13):1559-67. [PubMed:12127910 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Histamine receptor activity
Specific Function:
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamine release from adrenal medulla, as well as mediating neurotransmission in the central nervous system.
Gene Name:
HRH1
Uniprot ID:
P35367
Molecular Weight:
55783.61 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Richelson E, Nelson A: Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro. J Pharmacol Exp Ther. 1984 Jul;230(1):94-102. [PubMed:6086881 ]
  3. Noguchi S, Inukai T, Kuno T, Tanaka C: The suppression of olfactory bulbectomy-induced muricide by antidepressants and antihistamines via histamine H1 receptor blocking. Physiol Behav. 1992 Jun;51(6):1123-7. [PubMed:1353628 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1A
Uniprot ID:
P35348
Molecular Weight:
51486.005 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Thioesterase binding
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazoline > clonidine > epinephrine > norepinephrine > phenylephrine > dopamine > p-synephrine > p-tyramine > serotonin = p-octopamine. For antagonists, the rank order is yohimbine > phentolamine = mianser...
Gene Name:
ADRA2A
Uniprot ID:
P08913
Molecular Weight:
48956.275 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]
  2. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  3. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Rotzinger S, Fang J, Baker GB: Trazodone is metabolized to m-chlorophenylpiperazine by CYP3A4 from human sources. Drug Metab Dispos. 1998 Jun;26(6):572-5. [PubMed:9616194 ]
  2. Kalgutkar AS, Henne KR, Lame ME, Vaz AD, Collin C, Soglia JR, Zhao SX, Hop CE: Metabolic activation of the nontricyclic antidepressant trazodone to electrophilic quinone-imine and epoxide intermediates in human liver microsomes and recombinant P4503A4. Chem Biol Interact. 2005 Jun 30;155(1-2):10-20. Epub 2005 Apr 18. [PubMed:15978881 ]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  4. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A7
Uniprot ID:
P24462
Molecular Weight:
57525.03 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Wen B, Ma L, Rodrigues AD, Zhu M: Detection of novel reactive metabolites of trazodone: evidence for CYP2D6-mediated bioactivation of m-chlorophenylpiperazine. Drug Metab Dispos. 2008 May;36(5):841-50. doi: 10.1124/dmd.107.019471. Epub 2008 Jan 31. [PubMed:18238857 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
no
General Function:
Not Available
Specific Function:
Functions as transport protein in the blood stream. Binds various ligands in the interior of its beta-barrel domain. Also binds synthetic drugs and influences their distribution and availability in the body. Appears to function in modulating the activity of the immune system during the acute-phase reaction.
Gene Name:
ORM1
Uniprot ID:
P02763
Molecular Weight:
23511.38 Da
References
  1. Ferry DG, Caplan NB, Cubeddu LX: Interaction between antidepressants and alpha 1-adrenergic receptor antagonists on the binding to alpha 1-acid glycoprotein. J Pharm Sci. 1986 Feb;75(2):146-9. [PubMed:2870173 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Stormer E, von Moltke LL, Perloff MD, Greenblatt DJ: P-glycoprotein interactions of nefazodone and trazodone in cell culture. J Clin Pharmacol. 2001 Jul;41(7):708-14. [PubMed:11452702 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 09, 2016 02:39